Stockscreener 앱 받기
2.17
10.70%
-0.26
시간 외 거래:
2.17
전일 마감가:
$2.43
열려 있는:
$2.4
하루 거래량:
5.10M
Relative Volume:
2.44
시가총액:
$202.08M
수익:
$34.48M
순이익/손실:
$-102.07M
주가수익비율:
-1.4863
EPS:
-1.46
순현금흐름:
$-104.90M
1주 성능:
-12.15%
1개월 성능:
-4.41%
6개월 성능:
+146.59%
1년 성능:
-7.26%
1일 변동 폭
$2.13
$2.47
1주일 범위
$2.13
$3.535
52주 변동 폭
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
CRBU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.17 | 226.29M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Traders Purchase Large Volume of Caribou Biosciences Call Options (NASDAQ:CRBU) - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Given New $8.00 Price Target at Citigroup - MarketBeat
Truist Securities reiterates Buy rating on Caribou Biosciences stock By Investing.com - Investing.com Nigeria
Published on: 2025-11-04 03:55:22 - newser.com
How to build a custom watchlist for Caribou Biosciences Inc.Bear Alert & AI Powered Buy/Sell Recommendations - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthMarket Performance Summary & Risk Managed Trade Strategies - newser.com
Analyzing Caribou Biosciences Inc. with multi timeframe chartsWatch List & Reliable Price Breakout Alerts - newser.com
Comparing Caribou Biosciences Inc. in custom built stock radarsQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
What machine learning models say about Caribou Biosciences Inc.Earnings Risk Report & Community Verified Swing Trade Signals - newser.com
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - Investing News Network
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - Investing News Network
Is Caribou Biosciences Inc. stock a contrarian buy2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
Caribou Bio leaps on early data for vispa-cel - The Pharma Letter
CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus
Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com
Caribou Says Potential Non-Hodgkin Lymphoma Therapy Shows High Overall Response; Shares Rise Pre-Bell - MarketScreener
Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedSwing Trade & High Conviction Investment Ideas - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):